Relapse-free survival in subsets. (A) Reduction in WT1 after pretransplantation dose of immunotherapy. (B) Achievement of undetectable WT1 status at any time during the trial. (C) Achievement of undetectable WT1 status before ASCT. (D) Induction of autologous tumor DTH response (yes, ; no, –).